Celltrion Corona treatment supplied in mid-February… Pharmaceutical companies → Consultation on direct supply of medical institutions

A researcher at the Celltrion 2 plant in Yeonsu-gu, Incheon, is looking at Rekironaju (CT-P59), a COVID-19 antibody treatment. (News1 DB)/News1

The quarantine authorities announced on the 6th that Celltrion will temporarily purchase the new coronavirus infection (Corona 19) treatment “Recyronaju (ingredient legdanvimab)” and supply it to medical institutions from mid-February.

It means that the government will be directly involved in supplying the initial quantity as it takes time to purchase treatment contracts and prepare products for manufacturers.

Lee Sang-won, head of epidemiological investigation and analysis, central quarantine countermeasures headquarters (hereinafter referred to as Bang Dae-bon) of the Centers for Disease Control and Prevention (KCDC), said at a regular briefing on the day, “We plan to supply Rekkirona, which received conditional approval from the Ministry of Food and Drug Safety, to medical institutions from mid-February. .

He added, “The range of subjects to be administered the treatment will be finalized through expert review according to the effect approved by the Ministry of Food and Drug Safety.”

He continued, “We plan to discuss the supply of treatment products in the form of direct supply from pharmaceutical companies for smooth supply and demand.”

According to the Ministry of Food and Drug Safety,’Rekironaju’ is prescribed to patients with mild to moderate symptoms in high-risk groups over the age of 18. The high-risk group is mild, age 60 or older, or age 18 or older with underlying disease. Moderate patients are 18 years of age or older and have symptoms of pneumonia or whose pneumonia is observed through imaging. However, patients with severe pneumonia are excluded from treatment with Rekirona.

In addition, it is commonly prescribed when the oxygen saturation in indoor air exceeds 94% and no supplemental oxygen supply is required, and symptoms develop within 7 days prior to administration of the treatment. Food and Drug Administration Minister Kim Kang-rip said at a briefing on the 5th, “(Rekkironaju) is expected to be more effective in patients with high-risk mild and moderate symptoms than in severe patients.

[email protected]